Get Connected:


Latest News

FDA Approval of Opioid Withdrawal Device Highlights AJPB Week in Review
Top articles of the week from The American Journal of Pharmacy Benefits.
Medicare sequester cuts could restrict access to care for seniors with cancer.
Approximately 46% of Americans have high blood pressure, according to revised guidelines.
Mid-range levels of phosphate in the blood may reduce the risk of heart attack.
Less than half of diabetic foot ulcers heal within 1 year.
Top news of the day from across the healthcare landscape.
Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.
Emicizumab-kxwh is administered as a weekly subcutaneous injection to restore clotting ability in patients with hemophilia.
View More >

From the Journals

Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
In a review of publicly reported diabetes quality measures for Medicaid fee-for-service, overall reporting was low and reports of outcomes measures were rarely available.
This study assessed the impact of initiating hyaluronic acid injections on pain management pharmacotherapies utilization patterns in patients with knee osteoarthritis.
Initiation of treatment with guideline-recommended medications within 60 days of fibromyalgia diagnosis was associated with immediate annual healthcare cost savings.
The findings of a retrospective study suggest that timing of heart failure (HF)-related pharmacotherapy following a HF-related encounter has potential implications on subsequent healthcare costs.
Many healthcare stakeholders are concerned that pharmacy benefit managers use perverse incentives that work against healthcare goals, such as improved outcomes and lower costs.
For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.
Upcoming Partner Events